In operable non-small cell lung cancer (NSCLC), molecular residual disease (MRD) detection via circulating tumor DNA (ctDNA) has emerged as a promising approach to identify individuals at high risk of disease recurrence and potentially guide adjuvant therapy decisions.
To get things done fast at FDA: ‘Don’t tell anybody,’ cancer chief says
WASHINGTON — The Food and Drug Administration’s top cancer drug regulator doesn’t always ask for permission before taking on big initiatives. Richard Pazdur, director of
November 15, 2023